Chinese FDA approves two of China Medical's FISH probes
This article was originally published in Clinica
The Chinese state FDA (SFDA) has given the go-ahead to two of China Medical Technologies' fluorescence in situ hybridisation (FISH) tests – the Prenatal FISH probe and the Cervical Cancer FISH probe. The former detects extra copies of chromosome 13, 18 and 21, and sex chromosome additions or deletions. Having three copies of chromosomes 13, 18 and 21 leads to Patau's, Edward's and Down's syndromes, respectively. Well-known sex chromosome disorders include Turner syndrome, where females only have one sex chromosome (X), or Klinefelter's syndrome, where males have an extra X chromosome (XXY). The Cervical Cancer FISH probe detects amplification of the TERC gene in human cervical tissue, which has been linked with the severity of cervical disorders.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.